Illumina, Inc. $ILMN Stock Holdings Lowered by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 64.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,778 shares of the life sciences company’s stock after selling 23,313 shares during the period. Yousif Capital Management LLC’s holdings in Illumina were worth $3,497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Illumina during the second quarter worth about $3,374,423,000. Primecap Management Co. CA acquired a new position in shares of Illumina in the 2nd quarter valued at approximately $617,981,000. Jupiter Topco LLC acquired a new position in shares of Illumina in the 2nd quarter valued at approximately $358,652,000. WCM Investment Management LLC lifted its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Illumina during the 2nd quarter worth approximately $293,846,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ILMN. Citigroup increased their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Barclays raised their target price on Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. Finally, Leerink Partners lifted their price target on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $234.41.

Insider Transactions at Illumina

In related news, Director Keith Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Up 0.6%

Shares of NASDAQ ILMN opened at $271.04 on Tuesday. The company has a market cap of $40.93 billion, a price-to-earnings ratio of 52.31, a PEG ratio of 3.82 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $94.00 and a 12 month high of $309.35. The stock has a 50-day moving average price of $241.80 and a two-hundred day moving average price of $173.01.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the company posted $1.19 EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.